Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer

References

• Siegel RL, Miller KD, Jemal A. (2016). Cancer statistics, 2016. CA Cancer J Clin 66:7–30.
   PubMed Web of Science ®Google Scholar
• Holschneider CH, Berek JS. (2000). Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3–10.
   PubMed Web of Science ®Google Scholar
• Morgan RJ, Jr, Alvarez RD, Armstrong DK, et al. (2013). Ovarian cancer, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11:1199–209.
   PubMed Web of Science ®Google Scholar
• Dedrick RL. (1985). Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12:1–6.
   PubMed Web of Science ®Google Scholar
• Flessner M, Dedrick R, Rippe B. (1989). Estimation of lymphatic absorption and intraperitoneal volume during hypertonic peritoneal dialysis. ASAIO Trans 35:178–81.
   PubMedGoogle Scholar
• Jones R, Myers C, Guarino A, et al. (1978). High volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Cancer Chemother Pharmacol 1:161–6.
   PubMed Web of Science ®Google Scholar
• Miyagi Y, Fujiwara K, Kigawa J, et al. (2005). Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin—a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol 99:591–6.
   PubMed Web of Science ®Google Scholar
• Wright AA, Cronin A, Milne DE, et al. (2015). Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol 33:2841–7.
   PubMed Web of Science ®Google Scholar
• Huo YR, Richards A, Liauw W, Morris DL. (2015). Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol 41:1578–89.
   PubMed Web of Science ®Google Scholar
• Herzog TJ. (2012).The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax? Ann Surg Oncol 19:3998–4000.
   PubMed Web of Science ®Google Scholar
• Piso P, Dahlke MH, Loss M, Schlitt HJ. (2004). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2:1.
   PubMedGoogle Scholar
• Piso P, Dahlke M, Ghali N, et al. (2007). Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies. Int J Colorectal Dis 22:1295–300.
   PubMed Web of Science ®Google Scholar
• Di Giorgio A, Naticchioni E, Biacchi D, et al. (2008). Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113:315–25.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. (2003). Carcinomatosis-is cure an option? J Clin Oncol 21:762–4.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. (2007). Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol 95:93–6.
   PubMed Web of Science ®Google Scholar
• Los G, Sminia P, Wondergem J, et al. (1991). Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 27:472–7.
   PubMed Web of Science ®Google Scholar
• Los G, Van Vugt MJ, Den Engelse L, Pinedo HM. (1993). Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem Pharmacol 46:1229–37.
   PubMed Web of Science ®Google Scholar
• Los G, Van Vugt M, Pinedo H. (1994). Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 69:235–41.
   PubMed Web of Science ®Google Scholar
• Giovanella BC, Stehlin JS, Morgan AC. (1976). Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res 36:3944–50.
   PubMed Web of Science ®Google Scholar
• Hettinga J, Konings A, Kampinga H. (1997). Reduction of cellular cisplatin resistance by hyperthermia-a review. Int J Hyperthermia 13:439–57.
   PubMed Web of Science ®Google Scholar
• Reed E, Parker RJ, Gill I, et al. (1993). Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 53:3694–9.
   PubMed Web of Science ®Google Scholar
• Hotouras A, Desai D, Bhan C, et al. (2016). Heated intraperitoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. Int J Gynecol Cancer 26:661–70.
   PubMed Web of Science ®Google Scholar
• Helm CW. (2009). The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 14:683–94.
   PubMed Web of Science ®Google Scholar
• Ferron G, Simon L, Guyon F, et al. (2015). Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): a French multicentric survey. Eur J Surg Oncol 41:1361–7.
   PubMed Web of Science ®Google Scholar
• Ansaloni L, Coccolini F, Morosi L, et al. (2015). Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer 112:306–12.
   PubMed Web of Science ®Google Scholar
• Sánchez-García S, Villarejo-Campos P, Padilla-Valverde D, et al. (2016). Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): a clinical pilot study. Int J Hyperthermia 32:488–95.
   PubMed Web of Science ®Google Scholar
• Fagotti A, Petrillo M, Costantini B, et al. (2014). Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series. Gynecol Oncol 132:303–6.
   PubMed Web of Science ®Google Scholar
• Wright AA, Bohlke K, Armstrong DK, et al. (2016). Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:3460–73.
   PubMed Web of Science ®Google Scholar
• Bakrin N, Bereder JM, Decullier E, et al. (2013). Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 39:1435–43.
   PubMed Web of Science ®Google Scholar
• Ansaloni L, Agnoletti V, Amadori A, et al. (2012). Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 22:778–85.
   PubMed Web of Science ®Google Scholar
• Cascales-Campos PA. (2014). Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol 21:2383–9.
   PubMed Web of Science ®Google Scholar
• Rettenmaier MA, Mendivil AA, Abaid LN, et al. (2015). Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma. Int J Hyperthermia 31:8–14.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43.
   PubMed Web of Science ®Google Scholar
• Fagotti A, Costantini B, Petrillo M, et al. (2012). Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol 127:502–5.
   PubMed Web of Science ®Google Scholar
• Petrillo M, de Iaco P, Cianci S, et al. (2016). Long-term survival for platinum-sensitive recurrent ovarian cancer patients treated with secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 23:1660–5.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, White AJ, Weil SC, et al. (2013). Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 129:452–8.
   PubMed Web of Science ®Google Scholar
• Harrison ML, Gore ME, Spriggs D, et al. (2007). Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecol Oncol 106:469–75.
   PubMed Web of Science ®Google Scholar
• Le Brun JF, Campion L, Berton-Rigaud D, et al. (2014). Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study. Ann Surg Oncol 21:3621–7.
   PubMed Web of Science ®Google Scholar
• Polom K, Roviello G, Generali D, et al. (2016). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. Int J Hyperthermia 32:298–310.
   PubMed Web of Science ®Google Scholar
• Wagner U, Marth C, Largillier R, et al. (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107:588–91.
   PubMed Web of Science ®Google Scholar
• Harter P, Bois AD, Hahmann M, et al. (2006). Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–10.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. (2012). OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–45.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, et al. (2015). Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22:1570–5.
   PubMed Web of Science ®Google Scholar
• Classe JM, Glehen O, Decullier E, et al. (2015). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer. Anticancer Res 35:4997–5006.
   PubMed Web of Science ®Google Scholar
• Helm CW. (2012). Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am 21:645–63.
   PubMed Web of Science ®Google Scholar